Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial.

ABSTRACT:

Introduction

Functional cure has been proposed as an alternative to lifelong antiretroviral therapy and therapeutic vaccines represent one of the most promising approaches.

Materials and methods

We conducted a double-blind randomized placebo-controlled clinical trial to evaluate the safety, immunogenicity, and effect on viral dynamics of a therapeutic vaccine produced with monocyte-derived dendritic cells (MD-DC) loaded with a high dose of heat-inactivated autologous (HIA) HIV-1 in combination with pegylated interferon alpha 2a (IFNα-2a) in people with chronic HIV-1.

Results

Twenty-nine male individuals on successful ART and with CD4+ ≥450 cells/mm³ were randomized 1:1:1:1 to receive three ultrasound-guided inguinal intranodal immunizations, one every 2 wee

SUBMITTER: Leal L 

PROVIDER: S-EPMC8632026 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature